PLK1 and neoplasm: developed a novel strategy for the fabrication of a DNA‐NP for efficient delivery of sgRNA/Cas9/Antisense for targeting a tumor‐associated gene, PLK1.[128] The biocompatible DNA‐NP system demonstrated efficient inhibition of tumor growth without inducing systemic toxicity.